Overview
Disorders of pancreatic internal secretion primarily affect the exocrine function of the pancreas, impacting the production and regulation of digestive enzymes and bicarbonate necessary for proper digestion. These conditions can arise from various pathophysiological mechanisms, including disruptions in calcium signaling and alterations in neurotransmitter pathways such as serotonin (5-HT). Understanding these mechanisms is crucial for both diagnosing and managing conditions that impair pancreatic function, such as chronic pancreatitis, cystic fibrosis-related pancreatic insufficiency, and certain forms of acute pancreatitis. The interplay between calcium homeostasis and neurohumoral regulation provides a foundation for developing targeted therapeutic strategies aimed at restoring normal pancreatic secretion.
Pathophysiology
The regulation of pancreatic secretion involves intricate cellular processes, particularly centered around calcium dynamics and neurotransmitter signaling. In vitro studies utilizing 45Ca as a tracer have elucidated the critical role of calcium pools within subcellular compartments, notably mitochondria, in modulating calcium-dependent functions essential for pancreatic acinar cell activity [PMID:1203623]. These findings suggest that disruptions in mitochondrial calcium handling could underlie several secretory disorders, as calcium influx and efflux are pivotal for the activation of digestive enzyme secretion.
Further insights into the neurohumoral regulation of pancreatic secretion come from studies employing conscious rat models, where antagonists targeting 5-HT(3) and 5-HT(2) receptors significantly inhibited pancreatic secretion in response to various luminal stimuli [PMID:10833495]. This evidence underscores the importance of serotonin in the gut-brain-pancreas axis, indicating that serotonin receptors play a crucial role in mediating signals from the gastrointestinal tract to the pancreas. The involvement of these receptors highlights potential therapeutic targets for conditions characterized by excessive or dysregulated pancreatic secretion. In clinical practice, understanding these pathways can guide the development of receptor-specific antagonists as therapeutic interventions to modulate pancreatic function.
Diagnosis
Diagnosing disorders of pancreatic internal secretion often relies on assessing the functional state of pancreatic acinar cells, particularly focusing on calcium dynamics and secretory responses. Changes in calcium efflux and intracellular calcium concentration, especially in response to secretagogues like caerulein, serve as valuable biomarkers for evaluating pancreatic acinar cell function [PMID:1203623]. Elevated or abnormal calcium signaling patterns can indicate impaired regulation, suggesting underlying pathologies such as chronic inflammation or genetic mutations affecting calcium channels.
The use of specific receptor antagonists, such as L364,718 for 5-HT(3) receptors and ICS 205-930 for 5-HT(2) receptors, has shown promise in diagnostic assessments by effectively blocking pancreatic secretion responses [PMID:10833495]. These tools not only help in identifying the extent of neurohumoral influence on pancreatic secretion but also offer potential for monitoring treatment efficacy over time. Clinicians may consider incorporating these pharmacological probes into diagnostic protocols to gain deeper insights into the functional integrity of the pancreas and guide personalized treatment strategies.
Management
The management of disorders affecting pancreatic internal secretion often targets the underlying pathophysiological mechanisms, particularly focusing on calcium regulation and neurotransmitter modulation. Given that mitochondrial calcium levels are significantly influenced by secretory stimuli, therapeutic approaches aimed at stabilizing calcium homeostasis could be beneficial [PMID:1203623]. This might include pharmacological agents that modulate calcium channels or enhance mitochondrial calcium uptake and release mechanisms, thereby restoring normal secretory patterns.
In addition to calcium-targeted therapies, interventions that antagonize serotonin receptors, such as those studied with L364,718 and ICS 205-930, could play a role in managing conditions where excessive neurohumoral stimulation contributes to pancreatic dysfunction [PMID:10833495]. These strategies aim to reduce overstimulation of pancreatic acinar cells, potentially alleviating symptoms associated with hypersecretory states.
Lifestyle and Supportive Care
Emerging Therapies
Key Recommendations
By integrating these recommendations, clinicians can provide more effective and personalized care for patients suffering from disorders of pancreatic internal secretion, leveraging current understanding of cellular and molecular mechanisms to guide therapeutic decisions.
References
1 Clemente F, Meldolesi J. Calcium and pancreatic secretion-dynamics of subcellur calcium pools in resting and stimulated acinar cells. British journal of pharmacology 1975. link 2 Li Y, Hao Y, Zhu J, Owyang C. Serotonin released from intestinal enterochromaffin cells mediates luminal non-cholecystokinin-stimulated pancreatic secretion in rats. Gastroenterology 2000. link70373-8)
2 papers cited of 3 indexed.